Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Haag

Showing results (71-80 of 76) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 76 results.
Clinical Nutrition ESPEN|June 26, 2025
Individually compounded multi-chamber vs. standardized parenteral nutrition bags in solid tumors-A randomized clinical trial (IKF-010)Thorsten Oliver Goetze, Ralf-Dieter Hofheinz, Ingeborg Roetzer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 14, 2023
Perioperative Atezolizumab Plus Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel for Resectable Esophagogastric Cancer: Interim Results From the Randomized, Multicenter, Phase II/III DANTE/IKF-s633 TrialSylvie Lorenzen, Thorsten Oliver Götze, Peter Thuss-Patience, et al.
Gastroenterology|December 5, 2021
The Different Immune Profiles of Normal Colonic Mucosa in Cancer-Free Lynch Syndrome Carriers and Lynch Syndrome Colorectal Cancer PatientsLena Bohaumilitzky, Klaus Kluck, Robert Hüneburg, et al.
The Lancet. Oncology|October 26, 2016
Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trialSalah-Eddin Al-Batran, Ralf D Hofheinz, Claudia Pauligk, et al.
Lancet (London, England)|April 16, 2019
Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trialSalah-Eddin Al-Batran, Nils Homann, Claudia Pauligk, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 28, 2015
Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset, Josef Thaler, Richard Greil, et al.
Pageof 8

Showing results (71-80 of 76) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 76 results.
Clinical Nutrition ESPEN|June 26, 2025
Individually compounded multi-chamber vs. standardized parenteral nutrition bags in solid tumors-A randomized clinical trial (IKF-010)Thorsten Oliver Goetze, Ralf-Dieter Hofheinz, Ingeborg Roetzer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 14, 2023
Perioperative Atezolizumab Plus Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel for Resectable Esophagogastric Cancer: Interim Results From the Randomized, Multicenter, Phase II/III DANTE/IKF-s633 TrialSylvie Lorenzen, Thorsten Oliver Götze, Peter Thuss-Patience, et al.
Gastroenterology|December 5, 2021
The Different Immune Profiles of Normal Colonic Mucosa in Cancer-Free Lynch Syndrome Carriers and Lynch Syndrome Colorectal Cancer PatientsLena Bohaumilitzky, Klaus Kluck, Robert Hüneburg, et al.
The Lancet. Oncology|October 26, 2016
Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trialSalah-Eddin Al-Batran, Ralf D Hofheinz, Claudia Pauligk, et al.
Lancet (London, England)|April 16, 2019
Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trialSalah-Eddin Al-Batran, Nils Homann, Claudia Pauligk, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 28, 2015
Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset, Josef Thaler, Richard Greil, et al.
Pageof 8